Pfizer new focus for future $5 Billion in Annual sales

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Nextblockbuster

Rank: President [?]

Points: 2717 [?]

Votes: 15 Score: 3.8 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Pfizer new focus for future $5 Billion in Annual sales

posted on Jan 06, 2019 11:46AM

From RMBL from IV

https://www.businessinsider.com/pfizer-strategy-in-cancer-drug-development-sales-2019-1

A 'recipe' for cancer investments

Pfizer already has a presence in treatments for breast cancer and prostate cancer but is working to expand that. The company hopes that oncology franchises will start bringing in an additional $5 billion annually in the next several years.

Let’s hope Pfizer loves what they are seeing with Zen 3694, if they do i could see some sort of deal license or partnership or collaboration with Zenith in the next little while